Motzer, R. J., Park, S. H., McDermott, R. S., Porta, C., Heng, D. Y. C., Burotto, M., Iacovelli, R., Verzoni, E., Cutuli, H., Haanen, J., Suarez, C., Velasco, G. D., Valderrama, B. P., Westgeest, H. M., Yuan, S., Perini, R. F., Wang, D., Schmidinger, M. (2026). Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.lba417